Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study

Receptor‐interacting protein kinase 1 (RIPK1), a regulator of inflammation and cell death, is a potential therapeutic target in immune‐mediated inflammatory diseases (IMIDs). The objective of this phase IIa multicenter, randomized, double‐blind, placebo‐controlled study was to evaluate safety, toler...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2020-10, Vol.108 (4), p.808-816
Hauptverfasser:	Weisel, Kathleen, Berger, Scott, Papp, Kim, Maari, Catherine, Krueger, James G., Scott, Nicola, Tompson, Debra, Wang, Susanne, Simeoni, Monica, Bertin, John, Peter Tak, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Canada CD3 Complex - metabolism Dermis - drug effects Dermis - enzymology Dermis - immunology Dermis - pathology Double-Blind Method Female Humans Male Middle Aged Oxazepines - adverse effects Oxazepines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Psoriasis - diagnosis Psoriasis - drug therapy Psoriasis - enzymology Psoriasis - immunology Receptor-Interacting Protein Serine-Threonine Kinases - antagonists & inhibitors Receptor-Interacting Protein Serine-Threonine Kinases - metabolism Remission Induction Signal Transduction T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - metabolism Time Factors Treatment Outcome Triazoles - adverse effects Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!